drugset / Trial / NCT03099603

A Study of HTD1801 in Healthy Subjects

NCT03099603

Phase 1 Completed 32 enrolled HighTide Biopharma Pty Ltd
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.

Timeline

Start
2017-03-24
Primary completion
2017-07-11
Completion
2017-10-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator berberine ursodeoxycholate Small molecule 0.5 g
Comparator berberine ursodeoxycholate Small molecule 1 g
Comparator berberine ursodeoxycholate Small molecule 2 g
Comparator berberine ursodeoxycholate Small molecule 4 g